Use of ACE inhibitors and ARBs in hypertensive women of childbearing age
- 16 September 2008
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 33 (5), 507-511
- https://doi.org/10.1111/j.1365-2710.2008.00938.x
Abstract
Background and objective: Treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) during pregnancy can cause severe foetal abnormalities. This study aimed to identify the proportion of women of childbearing age taking ACE inhibitors or ARBs on referral to a tertiary Hypertension Clinic. Design: Retrospective cohort study. Methods: A cohort of female patients aged 16–45 years was identified from approximately 1500 new referrals from January 2004 to October 2006, excluding those not taking antihypertensive medication. ACE inhibitors and ARBs were grouped together for the purposes of the study. Contraceptive status was established where possible. Results: Forty seven of 101 (47%) women aged 16–45 years were taking an ACE inhibitor (35) an ARB (11) or both (1) of whom 26 (55%) were aged 16–40 years. In this younger group, eight were using no contraception and three were using barrier methods only. Conclusions: Many GPs continue to prescribe ACE inhibitors and ARBs to women of childbearing age. A quarter of women in the study were taking these agents and were 40 years or less; of these many were not using reliable contraception. These women are at risk of foetal malformation and poor perinatal outcomes if they become pregnant. The British Hypertension Guidelines may put younger women at risk if general practitioners are unaware of potential foetotoxic and teratogenic consequences of prescribing ACE inhibitors and ARBs to women of child bearing age.Keywords
This publication has 12 references indexed in Scilit:
- Major Congenital Malformations after First-Trimester Exposure to ACE InhibitorsNew England Journal of Medicine, 2006
- ACE Inhibitors and Congenital AnomaliesNew England Journal of Medicine, 2006
- Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonistsEarly Human Development, 2006
- Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IVJournal of Human Hypertension, 2004
- Angiotensin-II-receptor inhibitors in pregnancyThe Lancet, 2001
- Losartan and fetal toxic effectsThe Lancet, 2001
- The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathyKidney International, 1999
- Angiotensin-converting-enzyme inhibitors in early pregnancyThe Lancet, 1997
- Teratogen update: Angiotensin‐converting enzyme inhibitorsTeratology, 1994
- Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for useAmerican Journal Of Medicine, 1994